191 related articles for article (PubMed ID: 33228820)
1. Anthracycline-related acute cardiotoxicity in a very young Omani patient with acute myeloid leukaemia.
Tony S; Mevada R; Joshi N
Cardiol Young; 2021 Mar; 31(3):464-467. PubMed ID: 33228820
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines.
Mort MK; Sen JM; Morris AL; DeGregory KA; McLoughlin EM; Mort JF; Dunn SP; Abuannadi M; Keng MK
J Oncol Pharm Pract; 2020 Apr; 26(3):680-687. PubMed ID: 31500517
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom.
Temming P; Qureshi A; Hardt J; Leiper AD; Levitt G; Ancliff PJ; Webb DK
Pediatr Blood Cancer; 2011 Apr; 56(4):625-30. PubMed ID: 21298750
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review.
Hefti E; Blanco JG
Cardiovasc Toxicol; 2016 Jan; 16(1):5-13. PubMed ID: 25616318
[TBL] [Abstract][Full Text] [Related]
5. Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study.
Linares Ballesteros A; Sanguino Lobo R; Villada Valencia JC; Arévalo Leal O; Plazas Hernández DC; Aponte Barrios N; Perdomo Ramírez I
Colomb Med (Cali); 2021 Feb; 52(1):e2034542. PubMed ID: 33911320
[TBL] [Abstract][Full Text] [Related]
6. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
[TBL] [Abstract][Full Text] [Related]
7. Cardiac toxicity after anthracycline chemotherapy in childhood.
Iarussi D; Indolfi P; Galderisi M; Bossone E
Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
[TBL] [Abstract][Full Text] [Related]
8. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
9. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126
[TBL] [Abstract][Full Text] [Related]
10. Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients.
Zhou X; Weng Y; Jiang T; Ou W; Zhang N; Dong Q; Tang X
BMC Cancer; 2023 Oct; 23(1):976. PubMed ID: 37833648
[TBL] [Abstract][Full Text] [Related]
11. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia. Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zürich, Switzerland, between 1990 and 1996.
Dazzi H; Kaufmann K; Follath F
Ann Oncol; 2001 Jul; 12(7):963-6. PubMed ID: 11521803
[TBL] [Abstract][Full Text] [Related]
13. Disclosing an In-Frame Deletion of the Titin Gene as the Possible Predisposing Factor of Anthracycline-Induced Cardiomyopathy: A Case Report.
Chang YW; Weng HY; Tsai SF; Fan FS
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012532
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Creutzig U; Diekamp S; Zimmermann M; Reinhardt D
Pediatr Blood Cancer; 2007 Jun; 48(7):651-62. PubMed ID: 17183582
[TBL] [Abstract][Full Text] [Related]
15. Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: a North American perspective.
Orgel E; Zung L; Ji L; Finklestein J; Feusner J; Freyer DR
Pediatr Blood Cancer; 2013 Sep; 60(9):1528-33. PubMed ID: 23441080
[TBL] [Abstract][Full Text] [Related]
16. [Severe heart failure in consequence of late anthracycline-induced cardiotoxicity--case report].
Urbanová D; Bubanská E; Hrebík M; Mladosievicová B
Klin Onkol; 2009; 22(1):34-7. PubMed ID: 19534438
[TBL] [Abstract][Full Text] [Related]
17. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2014 Sep; (9):CD006647. PubMed ID: 25188452
[TBL] [Abstract][Full Text] [Related]
18. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal evaluation of anthracycline cardiotoxicity by signal-averaged electrocardiography in children with cancer.
Fukumi D; Uchikoba Y; Maeda M; Ogawa S
Pediatr Int; 2002 Apr; 44(2):134-40. PubMed ID: 11896869
[TBL] [Abstract][Full Text] [Related]
20. Case report and review of the literature: the utilisation of a ventricular assist device as bridge to recovery for anthracycline-induced ventricular dysfunction.
Krasnopero D; Asante-Korang A; Jacobs JP; Stapleton S; Carapellucci J; Dotson M; Stapleton G
Cardiol Young; 2018 Mar; 28(3):471-475. PubMed ID: 29198224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
